Eric Rose Acquires 30,310 Shares of Mesoblast Limited (ASX:MSB) Stock

Posted by on Jan 24th, 2025

Mesoblast Limited (ASX:MSB – Get Free Report) insider Eric Rose acquired 30,310 shares of the stock in a transaction dated Thursday, January 16th. The shares were bought at an average price of A$16.70 ($10.50) per share, for a total transaction of A$506,207.31 ($318,369.38).

Mesoblast Price Performance

The company has a debt-to-equity ratio of 24.76, a current ratio of 1.18 and a quick ratio of 1.82.

Mesoblast Company Profile

(Get Free Report)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Read More

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.